Cellectar enrolls first patient in Phase 1b CLR 125 trial for TNBC
PUBT · 04/14 12:36
Share
Listen to the news
- Cellectar Biosciences enrolled first patient in Phase 1b trial of CLR 125, an iodine-125 radioconjugate, in relapsed or refractory triple negative breast cancer.
- Trial will assess safety, tolerability, tumor targeting, and early signs of anti-tumor activity, with no clinical results presented yet.
- Management plans to report dosimetry, safety, and efficacy updates throughout 2026.
- Program builds on clinical experience with iopofosine I-131, while positioning CLR 125 as a differentiated candidate with a distinct therapeutic profile.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604140835PRIMZONEFULLFEED9689011) on April 14, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved